IMA-203 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase II program in Endometrial Cancer. According to Globaldata, it is involved in 3 clinical trials, of which 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of IMA-203’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for IMA-203 is expected to reach an annual total of $122 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
IMA-203 is under development for the treatment of solid tumors include hepatocellular carcinoma ovarian cancer, endometrial cancer, uterine cancer, sqNSCLC, subtypes of synovial sarcoma, uveal melanoma. It is based on XPRESIDENT, ACTengine platform and XCEPTOR platfom. XPRESIDENT is a target discovery engine which identifies tumor-associated peptides (TUMAPs) / T-cell targets. ACTengine platform uses autologous T-cells which are genetically engineered to express T-cell receptors upon lentiviral transduction which recognise targets identified by XPRESIDENT. These cells are expanded ex-vivo and reinfused back into the patient.It acts by targeting cells expressing preferentially expressed antigen in melanoma (PRAME).It is administered through intravenous route.
Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. Immatics is headquartered in Tuebingen, Germany.
The company reported revenues of (Euro) EUR172.8 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of EUR34.8 million in FY2021. The operating profit of the company was EUR30 million in FY2022, compared to an operating loss of EUR86.3 million in FY2021. The net profit of the company was EUR37.5 million in FY2022, compared to a net loss of EUR93.3 million in FY2021. The company reported revenues of EUR9.8 million for the first quarter ended March 2023, a decrease of 74% over the previous quarter.
For a complete picture of IMA-203’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.